


COBIS III, where are we from and where we go?

Bon-Kwon Koo, MD, PhD

Seoul National University Hospital, Seoul, Korea



COBIS study

- Investigator-initiated nation wide multicenter regist
- Endorsed by Korean Society of Interventional Car
- Sponsored and managed by Korean Bifurcation Club (KBC)


- KBC research committee
- Dedicated QCA core laboratory
- CRO
- Independent statistical analysis team
- Event adjudication committee

	COBIS I	COBIS II	COBIS III
Patients No.	1691	2897	2648
Enrollment period	2004.1~2006.6	2003.1 ~ 2009.12	2010.1 ~ 2014.12
Inclusion			
Main vessel Diameter, mm	≥ 2.5	≥ 2.5	≥ 2.5
Side branch Diameter, mm	≥ 2.0	≥ 2.3	≥ 2.3 (by QCA)
Left main bifurcation	X	0	0
DES generation	1 st	1 st + 2 nd	2 nd only
Median Follow-up Duration	25 months	38 months	53 months


What makes the difference?

Device? Concept? Technique?

TLF in LM bifurcation



TLF in non-LM bifurcation




What makes the difference?

Device? Concept? Technique?

- Safer access: More trans-radial approach
- Better stents and better stenting technique
- Better PCI technique: Better kissing, NC balloon, POT
- Better concept: imaging guidance, SB relevance
- Better risk stratification: SB occlusion, risk stratification

COBIS Registry

Transradial vs. Transfemoral for Bifurcation PCI





- LM bifurcation lesions from COBIS II (N=853)
- Transradial (N=212, 24.9%) vs. Transfemoral (N=641)
- Propensity score-matched analysis (1:2 ratio, 161 pairs)

	Transradial (N=161)	Transfemoral (N=322)	Adjusted HR (95% CI)	p
MACE	14 (8.7)	37 (11.5)	0.48 (0.22-1.03)	0.06
Cardiac death	4 (2.5)	5 (1.6)	0.33 (0.02-4.97)	0.42
Cardiac death or MI	7 (4.3)	8 (2.5)	1.42 (0.35-5.69)	0.62
TLR	7 (4.3)	32 (9.9)	0.30 (0.11-0.81)	0.02
TIMI major or minor bleeding	4 (2.5)	27 (8.4)		0.01

Korean Bifurcation Pooled Cohort



1st vs. 2nd generation DES





COBIS III registry

Clinical outcome among 2nd generation DES

SB No treatment group




SB Treatment group




What is the best 2-stent technique?

TAP technique? Culotte technique? DK crush technique?




What is the best 2-stent technique?

- N=673, treated with 2-stent technique (exclusion: kissing or V-stenting)



What is the best 2-stent technique?


- N=673, treated with 2-stent technique (exclusion: kissing or V-stenting)




COBIS III registry

What is the best 2-stent technique?

1-stenting
82.8%




Crush Technique
53.7%



COBIS III registry

What is the best 2-stent technique?



Numbers at risk

	0	1	2	3	4	5
Crush	244	210	187	152	108	64
T-stenting	125	104	94	85	66	39
Culotte	31	29	26	23	13	10
Kissing	41	35	32	27	17	11

Kang JH. KBC workshop 2019

Insight from COBIS II registry

What is the best 2-stent technique?

Subgroup	Patients	TLR (%)		Favor SB first	Favor MV first	Hazard ratio (95% CI)	p value	p for Interaction
		SB first	MV first					
MV RD								0.52
≥3.25 mm	217	12/120 (10.0)	12/97 (12.4)			0.80 (0.36-1.78)	0.59	
<3.25 mm	456	40/303 (13.2)	19/153 (12.4)			1.09 (0.63-1.88)	0.77	
SB RD								0.54
≥2.5 mm	276	20/151 (13.2)	19/125 (15.2)			0.92 (0.49-1.72)	0.79	
<2.5 mm	397	32/272 (11.8)	12/125 (9.6)			1.23 (0.63-2.38)	0.55	
SB RD > MV RD								0.78

Subgroup	Patients	TLR (%)		Favor SB first	Favor MV first	Hazard ratio (95% CI)	p value	p for Interaction
		SB first	MV first					
MV DS								0.04
≥70%	257	22/156 (14.1)	8/101 (7.9)			1.94 (0.86-4.36)	0.11	
<70%	416	30/267 (11.2)	23/149 (15.4)			0.71 (0.41-1.22)	0.22	
SB DS > MV DS								0.008
Yes	252	17/189 (9.0)	12/63 (19.0)			0.44 (0.21-0.92)	0.03	
No	420	35/234 (15.0)	19/186 (10.2)			1.54 (0.88-2.68)	0.13	
MV Lesion Length								0.01
≥18 mm	329	36/215 (16.7)	11/114 (9.7)			1.79 (0.91-3.53)	0.09	
<18 mm	344	16/208 (7.7)	20/136 (14.7)			0.53 (0.27-1.01)	0.05	

“MORE severe lesion FIRST” strategy for cases requiring systematic 2 stenting.

≥65°	293	27/167 (16.2)	14/126 (11.1)			1.53 (0.80-2.92)	0.20
<65°	380	25/256 (9.8)	17/124 (13.7)			0.72 (0.39-1.33)	0.29

0.1 1 10

What makes the difference?

Device? Concept? Technique?

- Safer access: More trans-radial approach
- Better stents and better stenting technique
- **Better PCI technique: Better kissing, NC balloon....**
- Better concept: Imaging guidance, SB relevance
- Better risk stratification: SB occlusion, risk stratification

“KISS” for 1-stent technique: Good or Bad?

	Number Design	Primary endpoint	Outcomes	Results	Memo
Niemela M (NORDIC III) Circulation 2011	N=477 RCT	6-mo MACE	FKB 2.9%, non-FKB 2.9% P=NS	Neutral	
Gwon HC (COBIS I) Heart 2012	N=1,065 Registry	2-year MACE	FKB 9.5%, non-FKB 4.5% p=0.02	Bad	Higher MV TLR in FKB group
Yamawaki M Circ J 2014	N=253 Registry	3-year MACE	FKB 14.6% vs. non-FKB 6.9% p=0.07	Bad	Higher MV restenosis in FKB-group
Kim TH Int J Cardiol 2014	N=251 Registry	3-year MACE	FKB HR=0.40 (95% CI 0.19–0.84), p=0.015	Good	ACS patients
Biondi-Zoccai G Heart Vessels 2014	N=2,813 Registry	2-year MACE	HR=1.01 (0.80–1.23) p=0.91	Neutral	
Gao Z Chin Med J 2015	N=790 Registry	4-year MACE	FKB: 7.8%, non-FKB 10.0% p=0.33	Neutral	Left main bifurcation
Kim YH (CROSS) JACC CVI 2015	N=306 RCT	1-year MACE	FKB 14.0%, non-FKB 11.6% p=0.57	Bad	Higher MV restenosis in FKB group
Yu CW (COBIS II) JACC CVI 2015	N=1,901 Registry	3-year MACE	HR=0.50 (95% CI: 0.30- 0.85),p = 0.01	Good	Lower MV TLR in FKB group

COBIS II Registry

“KISS” for 1-stent techniques

- Treated with 1-stent technique: N=1,901
- Final kissing ballooning (FKB): N=620 → PSM matched analysis: N=545 pairs

	Propensity-Matched Population			Standardized Difference
	FKB (n = 545)	Non-FKB (n = 545)	p Value	
After MV stenting				
Main vessel				
Proximal MLD	3.07 ± 0.55	3.02 ± 0.58	0.85	9.2
Middle MLD	2.76 ± 0.54	2.71 ± 0.56	0.72	9.6
Distal MLD	2.76 ± 0.49	2.72 ± 0.54	0.85	8.6
Side branch				
Ostial MLD	1.26 ± 0.73	1.25 ± 0.69	0.71	1.3
Distal MLD	2.02 ± 0.69	1.96 ± 0.68	0.67	7.8
Final				
Main vessel				
Proximal MLD				
Middle MLD	2.86 ± 0.50	2.72 ± 0.56	0.001	
Distal MLD	2.83 ± 0.48	2.73 ± 0.55	0.04	
Side branch				
Ostial MLD	1.85 ± 0.62	1.36 ± 0.69	<0.001	
Distal MLD	2.15 ± 0.59	1.99 ± 0.68	0.04	

FKB reduces main vessel TLR, not side branch TLR.
“Gentle KISS for MB and SB”


	Adjusted HR (95% CI)	p
MACE	0.50 (0.30-0.85)	0.01
Cardiac death	0.50 (0.11-2.29)	0.37
MI	0.18 (0.01-20.4)	0.48
Stent thrombosis,	0.77 (0.17-3.45)	0.73
	0.91	0.02
Main vessel	0.51 (0.28-0.93)	0.03
Side branch	0.57 (0.24-1.37)	0.21

COBIS II Registry

Clinical impact of NC balloon

- Use of non-compliant balloon: N=752, 26.0%
- Propensity score-matched analysis: N=710 pairs

	CB	NCB	p
Dissection >type B	1.1%	0.1%	0.046
Angiographic success			
Main vessel	99.0%	98.7%	0.80
Side branch	75.4%	79.7%	0.03
In-hospital MI	0.8%	0%	0.04




What makes the difference?

Device? Concept? Technique?

- Safer access: More trans-radial approach
- Better stents and better stenting technique
- Better PCI technique: Better kissing, NC balloon, POT
- **Better concept: imaging guidance, SB relevance**
- Better risk stratification: SB occlusion, risk stratification


COBIS Registry

IVUS guidance improves outcomes




COBIS II Registry

True vs. Non-true bifurcation lesions: Clinical relevance of SB




Focus on true bifurcation with large SB.


How large is large enough?




% ischemia: 15%



% ischemia: 11%



% ischemia: 10%



% ischemia: 12%



DECISION TREE LEARNING IS THE PROCESS OF CREATING/LEARNING A DECISION TREE FROM TRAINING DATA


RECURSIVE PARTITIONING
IS THE MOST COMMON STRATEGY FOR
DECISION TREE LEARNING

ID3 C4.5
CART CHAID

DECISION TREE LEARNING
ALGORITHMS BASED ON
RECURSIVE PARTITIONING


One branch? 2 branch? 3 branch? 2.8mm?
2.3mm? LCx dominance? D1/2 dominance?
Non-dominant?

..... To train and validate models to predict % FMM $\geq 10\%$, the entire CCTA dataset was split into training and validation sets (4:1). To build a decision tree model, the training and validation sets were used for **recursive partitioning with 10-fold cross-validation**. Information gain was used to selected attributes for **higher nodes**.....





Jeon WK, Koo BK, et al. Eurointervention, In press

Decision Tree for % FMM \geq 10%



Jeon WK, Koo BK, et al. Eurointervention, In press

Are you (un)happy with this?




Koo BK, LaDisa J, 2009

COBIS III Registry


Clinical relevance of SB opening

Non-True Bifurcation



Leave alone	1085	979	909	808	619	372
SB opening	212	191	175	151	118	69

True Bifurcation



Leave alone	600	549	495	434	332	230
SB opening	297	267	244	207	146	90

What makes the difference?

Device? Concept? Technique?

- Safer access: More trans-radial approach
- Better stents and better stenting technique
- Better PCI technique: Better kissing, NC balloon, POT
- Better concept: imaging guidance, SB relevance
- **Better risk stratification: SB occlusion, risk stratification**

How to avoid SB compromise after MV stenting?

- **How to protect SB?**
 - Jailed wire technique
 - SB predilation
 - Optimal stent sizing,

Predictors of SB occlusion from COBIS II

Variables	OR [95% CI]	p Value
SB DS \geq 50%	2.3 [1.59-3.43]	<0.001
SB lesion length (by 1 mm)	1.0[1.003-1.06]	<0.001
Proximal MV DS \geq 50%	2.3 [1.57-3.50]	0.03
Acute coronary syndrome	1.5 [1.06-2.19]	0.02
Left main lesions	0.3 [0.16-0.72]	0.005

Korean Bifurcation Pooled Cohorts

Predictors of TVF in 2-stent strategy

- Treated with 2-stent strategy: N=951

	Adjusted HR*	95% CI	p Value
Treated bifurcation in LM	2.09	1.43 – 3.03	<0.001
High SYNTAX score >32	2.00	1.28 – 3.14	0.002
Diabetes mellitus	1.41	1.00 – 1.99	0.05
Second-generation DES	0.26	0.12 – 0.57	0.001
Non-compliant balloon	0.53	0.36 – 0.79	0.002
Final kissing ballooning	0.44	0.29 – 0.68	<0.001

*Adjusted for age (continuous), acute coronary syndrome as presentation, preprocedural hemoglobin level, pre-procedural creatinine level, bifurcation angle (continuous), multi-vessel coronary disease, transradial approach, intravascular ultrasound, provisional approach, stenting techniques, total stent length in side branch (continuous).

Conclusion

- COBIS registry started with bifurcation PCI patients since 2004 are still ongoing with dedicated QCA core laboratory/CRO, independent statistical analysis team and event adjudication committee.
- Results of COBIS studies expanded our knowledge on bifurcation treatment and improved the patients' clinical outcomes.
- Ongoing COBIS III study will provide more insights on coronary bifurcation lesions and their treatment.